New ALS drug enters first human safety testing
NCT ID NCT06453668
Summary
This early-stage trial is testing the safety of an experimental drug called siplizumab in 48 adults recently diagnosed with ALS (Lou Gehrig's disease). Researchers will monitor patients for one year to see how their bodies handle the drug and check for side effects. The study will also measure whether the drug affects immune cells and disease-related markers in the blood.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Skåne University Hospital Malmö
RECRUITINGMalmo, 205 02, Sweden
Contact
-
Studieenheten Akademiskt Specialistcentrum
RECRUITINGStockholm, 171 77, Sweden
Contact
-
Umeå University Hospital
RECRUITINGUmeå, 901 85, Sweden
Contact
Conditions
Explore the condition pages connected to this study.